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Background: Obesity is a major health issue, and one of the leading causes of 
Obstructive Sleep Apnoea (OSA). OSA occurs when the upper airway is repetitively 
obstructed, either entirely or partially, whilst sleeping. This causes reduced or lack of 
airflow into the lungs, commonly resulting in snoring or disturbed sleep that leads to 
daytime sleepiness, increased risk of motor or work-related accidents, and overall 
impaired quality of life. As rates of obesity increase, it can be expected that so too will 
cases of OSA. Previous overseas research has found that overnight energy expenditure 
(EE) is greater when OSA is untreated, whilst Continuous Positive Airway Pressure 
(CPAP), the “gold standard” treatment, has been linked to weight gain due to a decrease 
in overnight energy expenditure but mechanisms are not well understood. This means 
losing weight may become more difficult with CPAP treatment. 
Objective: To determine if there is a decrease in overnight energy expenditure following 
the initiation of CPAP treatment in patients newly diagnosed with Obstructive Sleep 
Apnoea, who are living in the Wellington area.  
Design: In this pilot study, participants were recruited prior to their scheduled sleep 
assessment by means of polysomnography (PSG) (a multi-component sleep assessment 
tool) at the WellSleep Sleep Investigation Centre at Bowen Hospital. Participants were 
also recruited following PSG confirming OSA, but prior to initiating CPAP treatment.  
The study was divided into three stages. In stage one, participants wore a SenseWear® 
device on an armband consecutively for three days and nights, whilst keeping a three day 
food record and three day sleep diary. 
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In stage two, participants initiated CPAP treatment following OSA diagnosis, and 
continued to receive treatment.  
Stage three was identical to stage one, but whilst continuing CPAP treatment.  
Data on EE and sleep patterns were collected from SenseWear® devices by exporting the 
data to the SenseWear® Professional 8.1 program by Bodymedia® on a computer. Sleep 
diaries confirmed sleep data. Kai-culator (v 1.11), a University of Otago dietary analysis 
program, was used to calculate energy intake from food diaries.  
The strength of the relationship between CPAP and EE was measured using Pearson 
correlation coefficient. EE and energy intake before and during CPAP treatment were 
compared using paired t-tests. 
Results: Mean energy intake per day was 9629KJ (SD 3130) in stage one, and 9271KJ 
(SD 2107) in stage three, with no significant difference between each stage (p=0.89). 
Mean EE per hour of total sleep time was 351KJ (SD 86) in stage one, and 340KJ (SD 
82) in stage three, with no significant difference between each stage (p=0.36). CPAP use 
was strongly correlated with EE; EE decreased as hours of CPAP use increased (p=0.014, 
R2=0.485). 
Conclusion: The current study found a significant relationship between EE and CPAP; 
energy expenditure during sleep reduced with longer CPAP use. However, no overall 
differences in EE or EI were seen before and during initial CPAP use. 
 These results indicate there is the potential for weight gain to occur over time once 
initiated on CPAP treatment, particularly if energy intake remains unchanged. A longer 
term study with a larger sample size will help clarify the extent of this relationship. 
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Obstructive Sleep Apnoea (OSA) is a sleep related breathing disorder which occurs when 
the upper airway is repetitively obstructed, either entirely or partially, whilst sleeping. 
This causes reduced or lack of airflow into the lungs, commonly resulting in snoring or 
disturbed sleep that leads to daytime sleepiness, increased risk of motor or work-related 
accidents, and overall impaired quality of life (Qaseem et al., 2014, bpacnz, 2012.).  Major 
risk factors identified for OSA include obesity (40-90% of patients are obese (bpacnz, 
2012.)), increasing age, and male sex (bpacnz, 2012., National Institute for Health and 
Clinical Excellence, 2008). 
 
Co-morbidities that contribute to cardiovascular disease such as hypertension, diabetes 
and insulin resistance are also associated with OSA (Murri et al., 2009, Coughlin SR, 
2007, Marin et al., 2005, Gottlieb et al., 2014, Reichmuth et al., 2005).  
 
In New Zealand (NZ), OSA is estimated to affect approximately 4% of adult males and 
2% of adult females; the prevalence is higher than this amongst Pacific and Maori ethnic 
groups, who have more symptoms than New Zealand European and Other (NZEO) 
groups, and are more likely to suffer moderate or severe forms of OSA (Mihaere et al., 
2009). 
 
Continuous Positive Airway Pressure (CPAP) (the “gold standard” treatment) prevents the 




into the patient’s upper airway via a mask (Sullivan et al., 1981). CPAP improves sleep 
quality and overall quality of life (McMillan et al., 2014), and is a cost-effective way to 
manage the condition (National Health and Medical Research Council, 2000). 
 
Interestingly, some studies have found that CPAP leads to weight gain (Quan et al., 2013, 
Garcia et al., 2011); A meta-analysis published in 2015 showed a significant increase in 
BMI and body weight with use of CPAP (Drager et al., 2014). OSA patients have higher 
metabolic rates than those without OSA (Phillips et al., 2000, Kezirian et al., 2008), and 
CPAP reduces overnight energy expenditure (EE) in OSA patients by decreasing 
restlessness and movement overnight (Stenlof et al., 1996). 
 
Despite improved sleep quality and duration from using CPAP, research shows people do 
not change their diet or exercise habits; they do not experience a decrease in energy intake 
or an increase in energy expenditure (Ong et al., 2013).  People appear to only lose weight 
when using intensive lifestyle interventions, which have been shown to be very effective 
for reducing severity of OSA and any other co-morbidities present (Chirinos et al., 2014, 
Hood et al., 2013, Thomasouli et al., 2013, Johansson et al., 2011). However, if overnight 
energy expenditure decreases upon initiation of CPAP treatment, this may make weight 
loss somewhat more difficult for OSA patients who struggle with weight management. 
 
The overall aim of this project was to determine if newly or recently diagnosed OSA 
patients living in Wellington experience a change in overnight EE upon initiation and 




2. Literature Review 
 
2.1 Introduction and Methods 
Relevant literature was searched for on databases “CINAHL” and “Medline”. The first 
keyword used to search both databases was ‘sleep apnoea’. This was then linked with 
other keywords using ‘and’ such as ‘CPAP’, ‘CPAP and weight changes’, ‘weight 
changes’, ‘weight loss’, ‘weight gain’, ‘energy expenditure’, ‘energy expenditure and 
weight changes’. Citations in the found articles were also used to find more relevant 
journal papers.  
2.2 What is Obstructive Sleep Apnoea? 
Obstructive Sleep Apnoea occurs when the upper airway is repetitively obstructed, either 
entirely or partially, whilst sleeping, causing reduced or lack of airflow into the lungs. 
This commonly results in snoring and disturbed sleep (Qaseem et al., 2014).  A by-
product of OSA is daytime sleepiness, which impairs overall quality of life and is a 
potential hazard for motor or work-related accidents (Qaseem et al., 2014, bpacnz, 2012.).  
Major risk factors identified for OSA include obesity, increasing age, and male sex. 
Enlarged tonsils or tongue, or craniofacial abnormalities are also risks for OSA (bpacnz, 
2012., National Institute for Health and Clinical Excellence, 2008). 
Co-morbidities that contribute to cardiovascular disease such as hypertension, diabetes 
and insulin resistance are also associated with sleep apnoea (Coughlin SR, 2007, Murri et 
al., 2009, Marin et al., 2005, Gottlieb et al., 2014, Reichmuth et al., 2005). This may in 
part be due to the chronic hypoxia producing reactive oxygen species that lead to 




sympathetic stress from arousals (Murri et al., 2009, Gottlieb et al., 2014). It is important 
for OSA to be diagnosed so appropriate management and treatment can be given; this may 
aid in reducing these co-morbidities for the individual, as well as health care costs 
associated with these health issues (Mihaere et al., 2009).  
2.2.1 Tools to assist diagnosis 
The Epworth Sleepiness Scale (Johns, 1991) is often used to assess a patient’s degree of 
daytime sleepiness if they are suspected of having OSA. It is a subjective self-assessment 
tool, which gives a person a numerical score based on likeliness of falling asleep in eight 
different situations (Johns, 1991). The score indicates whether sleepiness is an issue. The 
Scale has been shown to have both high reliability and validity (Smyth, 2012). A score 
>10 is considered to mark excessive daytime sleepiness (Gander et al., 2005) and  is often 
used in conjunction with other measures to prioritise patients for clinical review (bpacnz, 
2012.). 
The Mallampati Score is a tool also used by health professionals (bpacnz, 2012.). It 
identifies the degree of airway obstruction, by asking the patient to protrude their tongue 
to determine the visibility of the tonsils, uvula and soft palate (bpacnz, 2012.). Scores are 
ranked from class one (complete visibility) to class four (no visibility). A score of class 
three or four indicates likely severe obstruction (bpacnz, 2012.). 
2.2.2 Diagnosis 
Following the above assessment and clinical history, Polysomnography is used to confirm 
a diagnosis of OSA. A multi-component sleep assessment tool, it measures and records a 




(skeletal muscle activity), electro-oculography (eye movements), heart rate, oxygen 
saturation, nasal flow, thoracic and abdominal movements, limb movements, and body 
position. A level 1 study is one carried out in a laboratory with an attending technician. A 
level 2 study has no attending technician and is often performed at the patient’s home 
(bpacnz, 2012.).  
In New Zealand, there is currently no agreed criteria for referring patients for sleep 
studies, although there are Australasian Guidelines on how and when to conduct sleep 
studies (Chai-Coetzer et al., 2014). People with co-morbidities such as cardiovascular 
disease or Type II diabetes, who suffer daytime sleepiness, or who have a motor or 
machine-operating related occupation are considered by experts to be of high priority for 
sleep studies (bpacnz, 2012.).  
During a sleep study, the Apnoea-Hypopnoea Index (AHI) is used as a severity indicator, 
and OSA is classified as mild, moderate or severe depending on the number of times a 
patient stops breathing per hour for longer than 10 seconds. An AHI of 5-15 is considered 
mild, 16-29 moderate, and >30 severe (bpacnz, 2012.).  
Partial sleep studies, also known as level 3 or 4 studies, can be carried out in a patient’s 
home by a trained technician (bpacnz, 2012.), (Chai-Coetzer et al., 2014). This is an 
alternative to a Sleep Study in a clinic or laboratory, and useful only in selected 
populations (Chai-Coetzer et al., 2014). Partial studies do not include all the 
measurements of a polysomnography. A type 3 partial study would include measuring 
airflow, respiratory effort, blood oxygenation and heart rate. This is considered the 




al., 2014). Type 4 only involves two measures (heart rate or airflow and blood 
oxygenation typically), which makes it difficult to differentiate between OSA and other 
sleep disordered breathing issues. Other information from the patient such as presence of 
snoring and sleep time can help compliment the data collected (Chai-Coetzer et al., 2014).  
2.2.3 Prevalence of OSA in New Zealand and overseas 
 
A survey by Mihaere et al. found that in NZ, OSA affects approximately 4% of adult 
males and 2% of adult females; the prevalence is higher in Pacific and Maori ethnic 
groups compared to NZ European and Other ethnic groups. Maori and Pacific people also 
appear to have more symptoms than  Non-Maori or Non-Pacific, and are more likely to 
suffer moderate or severe forms of OSA (Mihaere et al., 2009). 
Qaseem et al. estimated that between 10% and 17% of North Americans suffer from OSA. 
The estimate is not precise due to variation in criteria used to define OSA, and the number 
of individuals who may have a mild form of the disease but have not sought a diagnosis 
(Qaseem et al., 2014). In the UK, it is estimated that 4% of middle-aged men and 2% of 
middle-aged women have OSA; a similar prevalence to NZ (National Institute for Health 
and Clinical Excellence, 2008, Mihaere et al., 2009). 
2.2.4 Summary 
OSA is frequently associated with obesity, older age, and male sex. It is a full or partial 
obstruction in the upper airway, leading to snoring and disturbed sleep as a result of 
reduced or no airflow into the lungs. There are negative health outcomes if left untreated.  
The Epworth Sleepiness Scale, which has demonstrated reliability and validity, is used to 




OSA.  The Mallampati score can also be used to clinically identify the degree of 
obstruction. This should be followed by Polysomnography (a multi-component sleep 
assessment tool) to diagnose OSA. These can be carried out in a clinical setting, or in an 
individual’s home if appropriate. From these, the AHI is determined, which classifies as 
an individual as having ‘mild’, ‘moderate’, or ‘severe’ OSA.  There are differences in 
prevalence between genders and ethnicities.  If left untreated, OSA can contribute to 
conditions such as hypertension and cardiovascular disease, and consequent healthcare 
costs. 
2.3 Treatment for OSA 
The primary treatment option for moderate to severe OSA is Continuous Positive Airway 
pressure (CPAP) (National Institute for Health and Clinical Excellence, 2008). There are 
several treatment options available for those with mild OSA, and which can also 
complement CPAP treatment (bpacnz, 2012.).  
2.3.1 Continuous Positive Airway Pressure 
Sullivan et al first showed the effectiveness of CPAP in a small clinical trial (Sullivan et 
al., 1981). CPAP is recommended for people with moderate or severe OSA; the National 
Institute for Health and Clinical Excellence (NICE) Guidelines recommend it is only to be 
used in mild cases if other treatment has failed, and if quality of life is affected by 
symptoms (National Institute for Health and Clinical Excellence, 2008). CPAP is 
administered via a mask which the patient wears at night while sleeping. The device 
generates a continual pressure or airflow, which passes into the patient’s upper airway via 





“Compliance” to CPAP is classified as using it for at least 4 hours/night (National Institute 
for Health and Clinical Excellence, 2008). It is considered the “Gold Standard” treatment, 
but compliance is suboptimal for several reasons (National Institute for Health and 
Clinical Excellence, 2008). The mask can be uncomfortable if it fits poorly, or nasal 
dryness, bleeding or throat irritation may occur, resulting from pressure intolerance 
(bpacnz, 2012.).  
 
In both middle-aged and older adults, CPAP has been shown to improve sleep quality and 
overall quality of life (McMillan et al., 2014). It is also a cost-effective way to manage and 
treat the condition (National Health and Medical Research Council, 2000). 
Observational and intervention studies have also found that CPAP reduces blood pressure 
over several months, is associated with reduced risk of both fatal and non-fatal 
cardiovascular events (Coughlin SR, 2007, Marin et al., 2005, Gottlieb et al., 2014), and 
reduces glycated haemoglobin and cholesterol levels (Sharma et al., 2011). A Meta-
analyses of prospective observational studies published in 2013 also found CPAP 
treatment was associated with decreased cardiovascular mortality (Ge et al., 2013). A 
recent international study found that CPAP was effective in reducing blood pressure in 
patients with cardiovascular disease or multiple cardiovascular risk factors (Gottlieb et al., 
2014). Many studies have frequently found weight gain occurring following CPAP 
treatment. This will be discussed further in Section 2.5. 
2.3.2 Other Treatments for OSA 
Other treatments for OSA include weight loss, dental devices, surgery, reducing alcohol 





As obesity is a major risk factor for OSA, it would make sense that in theory weight loss 
should improve OSA or even completely treat the patient.  
Trials have shown weight loss to be effective in reducing severity and hence improving 
quality of life through reduced daytime sleepiness (Chirinos et al., 2014, Hood et al., 
2013, Thomasouli et al., 2013, Johansson et al., 2011). In a follow-up to a weight-loss 
trial, Johansson et al. found that one year later, weight loss as the result of a low energy 
diet had been maintained by the majority of participants. Obese men who had  lost the 
most weight or at baseline had the most severe OSA experienced the biggest decrease in 
OSA severity (Johansson et al., 2011). Bariatric surgery is also an option for morbidly 
obese people as it will reduce obesity, and potentially improve or cure OSA (Lanfranco et 
al., 2010).  
 
Dental devices may be useful for those suffering mild to moderate OSA, by increasing 
upper airway size to allow greater airflow into the lungs. Consequently, long-term use of 
the devices has been shown to reduce AHI and blood pressure (Marklund et al., 2012).  
 
Surgery is sometimes considered appropriate if OSA is caused by enlarged tonsils or 
tongue, or craniofacial abnormalities. This is of little use to those who are obese and 





Reducing alcohol intake, especially in the hours before bedtime, is helpful because alcohol 
promotes relaxation of the upper airway muscles, leading to a higher likelihood of 
collapse (Wettach et al., 2007). 
Drug treatments for daytime sleepiness can be an option, if sleepiness is still an issue 
despite CPAP compliance. Modafinil has been shown to be very useful alongside CPAP at 
reducing daytime sleepiness, and use does not affect an individual’s compliance to CPAP 
(bpacnz, 2012.) (Black, 2003).  
2.3.3 Summary 
The “gold standard” treatment for OSA, CPAP, has been shown in both observation and 
intervention studies to reduce co-morbidities and reduce cardiovascular mortality. 
Compliance may be affected if the mask does not fit properly, or nasal dryness, bleeding, 
or throat irritation occur from pressure intolerance. Other effective treatments include 
weight loss, changing sleeping positions, dental devices, surgery, reducing alcohol intake, 
and drug treatments. 
2.4 Current evidence for weight change following CPAP initiation in OSA patients 
No studies have been conducted in NZ looking at weight changes resulting from CPAP. 
Most have been conducted in the US, where obesity is a significant health issue, and a 
major risk factor for OSA. These studies classified use of CPAP at least 4 hours per night 
for at least 70% of nights as “compliant”, and all only used subjects who had an AHI >15 
(“moderate” OSA). A retrospective cohort, a randomised controlled trial (RCT), and a 
clinical trial, all found that CPAP was associated with weight gain (Quan et al., 2013, 
Redenius et al., 2008, Garcia et al., 2011). However there were limitations which may 





The multi-centre RCT of Quan et al. had the largest sample size and provides the strongest 
evidence of the three studies. Eight hundred and twelve participants were randomised to 
receive either CPAP (intervention) or Sham-CPAP (control) over 6 months. It was 
concluded that CPAP adherence may lead to some weight gain in OSA patients. However, 
adherence was suboptimal in both groups (only 35% adherence in entire cohort) (Quan et 
al., 2013). The primary aim of Garcia et al’s clinical trial was to investigate the metabolic 
effects of CPAP in 20 obese subjects, specifically looking at changes to insulin, insulin 
resistance, and ghrelin. Weight changes were associated with these factors. After using 
CPAP for 6 months nearly half of the participants had experienced weight gain. It is 
difficult to know if CPAP was responsible for this given the lack of data on any lifestyle 
changes participants may have made which could affect body weight. Weight change was 
also not a primary outcome in this study (Garcia et al., 2011).  
Conclusions drawn from  Redenius et al’s 2008 retrospective study stressed that 
Physicians should not assume CPAP alone will help obese patients with OSA lose weight, 
and that CPAP may affect weight in ways not measured in the study. The study found that 
BMI had significantly increased in women and non-obese subjects within one year of 
successfully using CPAP; no groups lost a significant amount of weight (Redenius et al., 
2008).   
 
In 2014, a meta-analysis which included 25 RCT’s and over 3000 participants was 
published. It showed that there was a significant increase in both BMI and body weight 




even after controlling for any diet and exercise counselling, and other potential 
confounders such as OSA severity, differences in study design, baseline BMI, and CPAP 
compliance. BMI however was influenced by baseline weight (Drager et al., 2014).     
As was explained in Section 2.4, weight gain may occur because CPAP normalises 
breathing, and so decreases energy expenditure whilst sleeping. 
 
A prospective study with a follow-up period of four to five years concluded that CPAP 
may facilitate short-term weight loss in overweight or obese people, but that they should 
be encouraged to lose weight through dietary measures (Loube et al., 1997).  
 
Other studies have found that weight loss in overweight or obese OSA patients has only 
occurred when participants have had to make a conscious effort to lose weight. Four 
different studies have found that if participants make a conscious effort to lose weight then 
this helps lower their AHI and risk factors for co-morbidities (Chirinos et al., 2014, 
Thomasouli et al., 2013, Johansson et al., 2011, Hood et al., 2013). The RCT published by 
Chirinos et al. found that a weight loss intervention combined with CPAP had a greater 
effect on blood pressure and other markers of metabolic syndrome than either intervention 
alone. It is not certain if CPAP had any role in weight loss (Chirinos et al., 2014). Hood et 
al. found a possible association between CPAP and weight loss, as participants 
randomised to a weight loss intervention lost more weight with increased CPAP 
adherence. However, the overall low CPAP adherence in both groups in this study limited 





The systematic review and meta-analysis of Thomasouli et al. found that CPAP and diet 
combined had the greatest effect on weight loss than either intervention alone. Studies 
which used intensive lifestyle interventions had a greater effect on weight loss than the 
trials which used intensive dietary intervention and CPAP only (Thomasouli et al., 2013). 
 
As mentioned in Section 2.3.2, Johansson et al. found improvements in the AHI of 
participants treated with CPAP when intentional weight loss through dietary intervention 
occurred, and this weight loss was able to be maintained one year after the intervention 
had ended (Johansson et al., 2011). 
 
The current evidence shows that CPAP contributes to weight gain, and that weight loss 
only occurs with intensive lifestyle intervention. Studies conducted in this area do have 
significant limitations. For example, the majority of participants are white males; results 
may not be relevant to females or relevant to New Zealand’s multi-ethnic society. Poor 
adherence to CPAP treatment is also an issue. 
2.4.1 Summary 
Studies led by Quan, Garcia, and Redenius concluded that CPAP was associated with 
weight gain. However, these studies were potentially affected by poor CPAP adherence, 
lack of data on lifestyle change, and retrospective design, respectively (Quan et al., 2013, 
Garcia et al., 2011, Redenius et al., 2008). People with OSA appear to only lose weight 
when making a conscious effort or using intensive lifestyle interventions. Weight loss 





2.5 Proposed mechanisms of how OSA and CPAP might influence weight changes 
Understanding mechanisms of how OSA and CPAP may affect body weight can give 
insight into why weight gain may occur.  
 
It is proposed that when untreated, OSA leads to increased overnight EE in at least two 
different ways: Chronic Intermittent Hypoxia (CIH), and increased work of breathing due 
to upper airway resistance. 
CIH causes increased sympathetic nerve activity. This leads to an increase in blood 
pressure, increased muscle activity (Lusina et al., 2006), and possibly endocrine 
abnormalities (Garcia et al., 2011) through altered release of hormones (Phillips et al., 
2000).  
 
Garcia et al. state this may lead to disruption of appetite and weight regulation hormones 
in people with OSA, which can be corrected through preventing hypoxia via CPAP use. 
They hypothesised that CPAP will increase levels of hormones that induce weight loss 
and reduce appetite; specifically that it would reduce insulin resistance and ghrelin levels, 
and increase adiponectin levels. Leptin levels were also examined for any change. After 6 
months of CPAP use, participants’ leptin and ghrelin levels were unchanged, and insulin 
and insulin resistance surprisingly increased only in those who experienced weight gain. 
Forty percent of participants who experienced weight loss showed a decrease in insulin 
and insulin resistance, whilst ghrelin changes were inversely correlated with insulin and 




hypoxia, only body weight changes affected participant’s hormones, meaning OSA 
doesn’t independently lead to weight or appetite dysregulation.  
 
Phillips et al. found OSA patients had significantly higher muscle sympathetic nerve 
activity than control subjects, and higher levels of leptin. They hypothesised that because 
muscle sympathetic nerve activity would likely be higher in OSA patients, that leptin 
levels would be lower due to suppression of its production (Phillips et al., 2000). This 
would explain obesity and tendency to gain weight in OSA patients. Higher levels of 
leptin are produced as a result of increased adipose tissue. It helps weight loss by 
mediating satiety and leading to excess fat stores being used as energy (Myers et al., 
2008). However, the researchers found that both sympathetic nerve activity and leptin 
levels were higher in OSA patients compared to healthy controls. The study therefore 
suggests that OSA may be associated with resistance to the effects of leptin, resulting in 
weight gain. “Leptin resistance” has been suggested to be an underlying mechanism  in 
continuing obesity in sleep apnoea patients, but not involved in the initiation of obesity 
(Myers et al., 2008).  
 
In a review of OSA and endocrine function, Lanfranco et al summarised leptin resistance. 
The serum levels or secretory patterns of many hormones are altered in response to 
obesity, but this alteration is exacerbated when OSA exists. There is evidence that insulin 
and leptin show increased levels in obesity with OSA, along with decreased levels of 





Indirect calorimetry with eight OSA subjects and 86 control subjects has found that as 
hypoxia increased, sleeping metabolic rate decreased (Hins et al., 2006). This also meant 
that as hypoxia decreased in response to CPAP, sleeping metabolic rate and hence EE 
increased. However, this result perhaps should not be taken as conclusive due to the low 
number of OSA subjects. In 2008 Kezirian et al. also used indirect calorimetry to assess 
EE of 212 OSA patients. Higher resting EE was independently associated with increased 
AHI and hence increased severity of OSA (Kezirian et al., 2008).  
 
Overnight EE also increases in OSA due to increased work of breathing, as a result of 
upper airway resistance (Stenlof et al., 1996, Marcus et al., 1994). The increased 
respiratory effort is also associated with restlessness or “tossing and turning”, as well as 
excessive perspiration which is also a symptom of OSA (Guilleminault and Abad, 2004). 
 
Energy expenditure (EE) in OSA patients has been measured to try to better understand 
the effect of OSA and CPAP on weight.  Stenlof et al. conducted a small pre- and post- 
treatment comparison trial with eleven subjects, which found over a period of 3 months 
that 24-hour EE and sleeping EE was higher for patients with OSA. CPAP normalised 
breathing and decreased overall restlessness and movement at night, and so decreased EE 
(Stenlof et al., 1996). Prior to this, Marcus et al. found that young children with untreated 
OSA had increased EE, which caused faltering growth (Marcus et al., 1994). 
When OSA is untreated, lethargy and daytime tiredness lead to less physical activity and 
higher consumption of energy-dense foods (Ong et al., 2013). Booth et al. found that sleep 




been observed that subjective hunger and appetite ratings increase with sleep restriction, 
as well as favour of high carbohydrate, energy-dense foods; this occurs in proportion to an 
increase in ghrelin and decrease in leptin (Spiegel et al., 2004).  
 
Perhaps with CPAP, people will make better choices around diet and activity as a result of 
improved sleep patterns. However, it has been shown that despite improved sleep quality 
and duration, participant’s dietary habits and activity levels do not substantially change 
(Ong et al., 2013, Batool-Anwar et al., 2014).  Although participants had improved sleep 
and hence less energy expenditure at night, there was no change in energy expenditure 
during the day following CPAP initiation (Ong et al., 2013). Quan et al. also propose that 
there is a reduction in overnight EE when compliant with CPAP, which may lead to some 
weight gain if energy intake is not modified (Quan et al., 2013). 
2.5.1 Summary 
EE is higher when OSA is not treated, compared to treatment with CPAP. This has been 
seen in both children and adults. Changes to endocrine function also occur due to hypoxia, 
potentially leading to “leptin resistance” and impaired regulation of weight management. 
Daytime sleepiness and short sleep duration are strong predictors of lower activity levels, 
increased subjective hunger scores, and favour of energy-dense foods. 
CPAP treatment normalises breathing and so reduces EE whilst sleeping. If lifestyle 
factors remain unchanged after CPAP treatment begins, then weight gain may likely 




3. Objective Statement 
 
Obesity is a major cause of OSA. As rates of obesity increase, it can be expected that so 
too will cases of OSA. Unfortunately, current overseas evidence suggests losing weight 
may become more difficult when using CPAP, likely due to a decrease in overnight 
energy expenditure. To the knowledge of the candidate and the Supervisor, no studies 
have been conducted in New Zealand looking at energy expenditure and CPAP. Therefore 
the major aim of this pilot study was to determine if a decrease in overnight energy 
expenditure following the initiation of CPAP treatment in adults with OSA who live in the 
Wellington area, could be detected.  
 
The primary objectives were to: 
 
 Determine if there are differences in overnight EE before and after initiating CPAP 
treatment. 
 Determine if there is any difference in EI before and after initiating CPAP 
treatment.  
 Determine if there are differences in Total Sleep Time (TST), before and after 






4. Subjects and Methods 
4.1 Study Design 
 
The aim of the study was to determine if there is a decrease in overnight EE upon 
initiation of CPAP treatment. The study protocol had three stages. In stage one, baseline 
data were collected for three consecutive days. This included continually wearing the 
SenseWear® device and completing food and sleep diaries. 
In stage two, participants diagnosed with OSA initiated CPAP treatment.  
Stage three repeated stage one, while using CPAP treatment and took place at least two 
weeks after stage two.  
4.2 Recruitment of participants 
 
The Human Ethics Committee of the University of Otago approved the study (Ethics 
Committee reference number H15/018). Prior to participating in the study, written 
informed consent was obtained from each participant.  
23 participants were approached between July and September 2015, using WellSleep 
referrals and consent to research participation while under WellSleep’s care. Potential 
participants were contacted by phone and/or email either at least one week prior to a 
scheduled split night PSG (combined diagnostic test for OSA and CPAP titration), or 
following diagnostic-only PSG confirming OSA but prior to initiating CPAP.  
 
Participants had to be at least 18 years of age, living within the Wellington area, and have 
enough literacy and numeracy skills to fill in the food and sleep diaries. Exclusion criteria 
included having a job involving shift work, having Periodic Limb Movements in Sleep 




Participant information sheets (PIS) (Appendix A) were given to the WellSleep registrar 
and other doctors who refer patients to the WellSleep Clinic for suspected OSA, so that 
patients could have some time to think about participating before they were approached.  
Participants who were sent an email (Appendix D) also received an attached copy of the 
Flow chart of the different stages of the study (Figure 4.1) and the PIS, asking them to 
consider participating in the study and notifying them that the candidate would telephone 
them later in the week to discuss possible participation. 
 
At the end of the study, participants who had come into the clinic to pick up and drop off 
the equipment were given a $20 MTA gift voucher to reimburse travel costs to and from 
the clinic. Contact for appropriate dietetic advice was provided if requested. SenseWear® 
reports were sent to participants who were interested in seeing their results at the end of 





Figure 4.1: Flow chart of the different stages of the study and approximate time 





4.3 Data Collection 
 
Once participants had been contacted and expressed interest in participating, they attended 
the clinic at least four days prior to their scheduled split PSG or CPAP initiation. During 
this visit they were taught how to wear the SenseWear® device (Appendix H) and how to 
complete the food and sleep diaries. If they were unable to come into the clinic, the 
candidate arranged to visit the participant in their home.  
 
The candidate allocated each participant an identification code to use for all data entry and 
analysis. Demographic information (age, sex, ethnicity (self-designated)), BMI, and 
existence of co-morbidities were collected using participant’s medical notes upon 
recruitment. Any missing or unclear data was obtained from the participant during their 
clinic visit. NZ Deprivation Index was assigned according to the 2013 Statistics New 
Zealand Census data. Each participant’s address was entered into the Statistics New 
Zealand Classification Coding System (v 4.0.2), using the ‘manual search’ option 
followed by ‘Geographic – Streets MB13’.  A score out of 10 was assigned for each 
address, in which 1 indicated the lowest level of deprivation and 10 indicated the highest 
level.  
 
In the appointment, the participant was asked to read and sign the consent form (Appendix 
C) once they had read the information sheet and had any questions answered. They were 
given a folder containing a Sleep Diary with instructions (Appendix G), a food record and 





At the end of Stage one, the participants returned the diaries and the SenseWear® device 
to WellSleep. They then collected their CPAP/Auto-PAP machine, or had their scheduled 
split PSG.  
 
If undergoing a ‘diagnostic only’ study, initially this was performed either at WellSleep or 
at home. A study carried out in an individual’s home had all the same measurements as 
one carried out at WellSleep except for video recording. Polysomnography consisted of 
the following measurements: Electroencephalogram, Electromyogram, Electro-
Oculogram, heart rate, Nasal and oral airflow, respiratory effort, leg movements, body 
position, sound (to hear snoring), and oxygen saturation. If the participant was put on 
CPAP treatment during the night (a ‘split night’ study), then CPAP pressure, mask leak 
and airflow were also assessed as per WellSleep study protocol.  
 
Following a ‘split night’ study, participants began CPAP use at home the following night 
(stage two). After home or diagnostic only studies, the participant initiated CPAP 
treatment as soon as convenient once OSA diagnosis was confirmed by the Sleep 
Physician responsible for the area. An appointment was made for the participant to return 
to the clinic to begin stage three once they had been on CPAP for at least 14 nights.  
 
For stage three, the participants picked up a second food and sleep diary, and the 
SenseWear® device. They were asked to collect data on the same days of the week as they 




When the participants returned their materials at the end of stage three, they were also 
asked to bring in their CPAP data card, so usage data could be downloaded per participant 
and use of CPAP determined.  CPAP compliance in this study was defined as use of the 
machine for at least four hours on average during stage three. Usage data from CPAP and 
Auto-PAP machines was downloaded from the machines data card using the appropriate 
company software. This generated a report of how many nights the machine had been used 
and average number of hours of use each night, both during stage two and three.   
4.3.1 SenseWear Device® 
 
The participants were instructed to wear the SenseWear® device consecutively for three 
days and nights, and to remove the device only when showering or bathing. In the initial 
appointment, the device was trialled on the non-dominant arm to ensure the armband was 
the right fit and to show participants how it was to be worn; on the mid upper arm, so that 
the device had contact with the triceps muscle. It was explained that SenseWear® was for 
assessing EE and total sleep times (TST). The participants’ name, birthday, sex, 
handedness, weight and height (self-reported or measured) were entered into the 
SenseWear® program and loaded onto the device to aid EE monitoring. 
 
The SenseWear® device gives accurate and continuous data for monitoring sleep and 
activity patterns in a person’s own environment (Sunseri et al., [No date]).  
SenseWear® has high reliability and validity, is accurate at detecting differences between 
sleep and sedentary activity, and can detect sleep onset, wake time, and total sleep time 




The SenseWear® device has several different sensors to assess multiple physiologic 
changes that mark changes in EE, making it more reliable and precise compared to other 
available instruments for assessing a person’s lifestyle (Liden et al., [No date]). It has an 
accelerometer which measures the wearer’s motion and steps; a thermistor-based sensor 
which measures skin temperature; a near-body ambient temperature sensor which 
measures the air temperature immediately around the armband, to detect the environment 
conditions the wearer is in; a galvanic skin response sensor to assess skin conductance, 
which is affected by sweat from physical activity and emotional stimuli; and a heat flux 
sensor which measures heat being dissipated by the body (Sunseri et al., [No date], Liden 
et al., [No date]). BMI, handedness (left or right handedness), smoking status, age and sex 
data are programmed into the device via computer to help calculate EE of the Wearer (St-
Onge et al., 2007).  
 
Using a variety of subjects with different medical conditions (for example, Type Two 
Diabetes and Chronic Obstructive Pulmonary Disease), SenseWear® has been found to 
have correlated well against indirect calorimetry in many laboratory tests. An average 
error of 3% was found compared to indirect calorimetry during exercise periods (Andre et 
al., 2006). The armband also provides day-by-day data to calculate EE, unlike indirect 
calorimetry methods such as Doubly Labelled Water (St-Onge et al., 2007). 
4.3.2 Sleep Diary 
 
Participants were also given sleep diaries to self-measure periods of sleeping and waking. 
Instructions with an example night were attached to help participants fill in the diaries. 




4.3.3 Estimated food record 
 
Participants were given a food diary with instructions and a ‘Diet Assessment Photo’ 
book, both created by the University of Otago Human Nutrition department. The book 
was to help participants with estimating portion sizes; it contains photos of different 
portion sizes of commonly consumed foods, including meat, rice, mixed vegetables, and 
cornflakes, and differing thickness of spreads on bread. Circles of different diameters are 
included to measure round foods such as apples, and a graph with measurements to 
measure square foods, such as slices of cheese. Each book also contained a sheet stating 
the weight of each portion size of every food shown in the book, for the candidate’s use. 
Food diaries were to be filled out according to the instructions provided with them, for the 
period the participants were wearing the SenseWear® device. If a participant forgot to 
take their food diary with them somewhere, or it was inconvenient to do so, they were 
instructed to record the data as best as they could on their cellphone using a note-taking 
app such as Evernote, and/or take a photo of the food to help them fill in the food diary 
later in the day.  
Estimated food records are one of several methods of dietary assessment.  
 
The participant records all food and beverages as they are consumed, the estimated 
amount, and other details of the food or beverage such as brand and method of preparation 
or cooking if applicable. A combination of the following can be used to determine portion 
sizes of foods: cup, spoon, or ruler measurements; labels on packaging; and photos of 




quantifying of portion sizes, lack of detail about food or beverage items, and undereating 
due to the burden of recording (Gibson, 2005).  
4.4 Data Entry 
 
At the end of both stage one and stage three for each participant, data from the 
SenseWear® devices were exported to a computer via USB cable for analysis in the 
SenseWear® Professional 8.1 program by Bodymedia®.  
 
At the end of stage one, information on the three sleep periods of each participant 
(according to their sleep diary) were downloaded as graphs, and from this kilojoules 
expended per hour of sleep was calculated. 
 
At the end of stage three, energy expenditure during the hours of sleep when CPAP was 
used was determined. From this, the kilojoules expended per hour of CPAP use were 
calculated.  
 
In both stage one and three, TST was also collected from SenseWear® data. 
Data from food diaries was analysed using the program Kai-culator (Version 1.11), 
developed by the University of Otago’s Department of Human Nutrition. Kai-culator uses 
the New Zealand Plant and Food Research FOODfiles to analyse dietary information. It 
includes information on the composition of foods available in New Zealand. 
 
Diet records were entered under the participant’s identification code, and the amounts of 




was unclear or in not enough detail, the participant was emailed and asked for clarification 
about the specific items in order to improve energy intake estimation. Kilojoule intake for 
two 24 hour periods was measured, and the average of the two periods recorded. 
4.5 Statistical Analysis 
 
All data collected was then recorded into a Microsoft Excel 2010 spreadsheet for further 
analysis. The statistical program SPSS (v. 22) was also used for analysis. Means and 
standard deviations were calculated using both programs. Percentages were calculated for 
categorical characteristic variables. Paired t-tests were used to calculate differences in 
both EE and EI before and after use of CPAP. Variables were checked for normality by 
producing histograms and box and whisker plots.  
 
Comparisons between stage one and stage three EE, EI, TST, and SenseWear wearing 
time were calculated using Paired samples t-tests, assuming normal distribution 
The average hours of CPAP use between those who experienced an increase in EE and 
those who experienced a decrease was calculated using Independent samples T-test, using 
Levene’s test for Equality of Variances. A Mann-Whitney Test was also used in case of  
non-normal distribution. 
 
The strength of relationship between CPAP use and change in EE was assessed using the 
Pearson correlation coefficient. Due to the very small sample size, EE and CPAP use 








In total, 15 participants were recruited between July and September 2015. Of these, four 
were excluded from the study; one participant did not have an OSA diagnosis after their 
PSG, one chose not to complete the study, and two did not use their prescribed CPAP 
treatment.  Completion rate was therefore 73%.  
5.1 Participant and Demographic data 
 
Table 5.1 summarises participant characteristics. Participants were predominantly male, 
and New Zealand European (90.9%). Mean ESS score was 9.1/24 ± 5.9. The majority of 
participants were in quintiles 1-3 (out of 10) of the NZ Deprivation Index (least deprived). 
All participants had a BMI classified as overweight or obese. 41.6% had one or more co-
morbidity, the most common of which was hypertension.  
 
Table 5.1: Participant characteristics a       (n=11) 
Age in years 53 (16.8) 

















ESS (/24) 9.1 (5.9) 
BMI (kg/m2) 35.8 (6.6) 
Co-morbidities present (%) 
Hypertension 














5.2 Dataset Completion 
 
Sunday and Saturday were the most common days of the week of which data were 
collected (Table 5.2). No data were collected on a Wednesday in stage one, but in stage 
three they were as one participant forgot to start collecting on the right day.   
 
Table 5.2: Frequency that each day of the week was used in data collection 
Day of week Frequency of recording  
 Stage one Stage three  
Sunday 8 7 
Monday 6 6 
Tuesday 4 4 
Wednesday 0 1 
Thursday 4 3 
Friday 6 5 
Saturday 8 7 
 
Oxygen desaturation and AHI were assessed during PSG, as part of OSA diagnosis. Mean 
oxygen desaturation associated with respiratory events was 6.36% ± 3.1. Most subjects 
were diagnosed with severe OSA (AHI>30). Mean AHI was 41 ±18.5 (Table 5.3).  
 









Mean Oxygen Desaturation associated  




5.2.1 Use of SenseWear 
During stage one, SenseWear devices were worn on average for a total of two days 20 
hours. 




There was no significant difference between the duration of the two wear times (p=0.61). 
5.2.2 Sleep Diary and Estimated Diet Record Completion 
 
All participants recorded sleep and wake times for at least three consecutive nights for 
both stage one and stage three, with the exception of one participant who forgot to 
complete the diary in stage three. 
All participants completed at least three consecutive days of estimated diet records in 
stage one and stage three. 
5.2.3 CPAP use 
 
Average CPAP pressure, average length of stage two, and mean hours that CPAP was 
used by participants over the three nights of stage three are shown in Table 5.4.  
The mean length of stage two (CPAP initiation) was 30.8 days ± 15.1. 
During stage three, CPAP was used on average for over five hours each night. Of the 11 
participants, only two used CPAP for less than 4 hours per night on average.  
In the three nights recorded in stage three, six of the participants had at least one night 
where they used CPAP for less than 4 hours.  
 
Table 5.4: CPAP use and machine pressure a 
CPAP pressure (cm H2O) 9.3 (2.1) 
 














5.3 Differences in sleep time, EE, and EI. 
 
Table 5.5 below shows differences in: TSTSW (period that SenseWear determined 
participant was sleeping); TSTSD (period that participant was asleep, according to 
subjective sleep diary); kilojoule consumption (EI); and kilojoule expenditure (EE) per 
hour of sleep, both before and during CPAP. There was no significant difference between 
stages one and three for any of these variables. 
 
Table 5.5: Summary of Total Sleep Time, Energy Intake, and Energy Expenditure 
before and after initiation of CPAP a 





TSTSW (hours) 5.73 (1.2) 5.87 (1.2) 0.77 



























TSTSW = Total Sleep Time according to SenseWear data (objective).  TSTSD = Total Sleep 
Time according to Sleep diary data (subjective).  a Results are presented as mean (SD). 
 
5.3.1 Energy Expenditure 
 
Overall, six participants experienced a decrease in EE (mean % change), all of whom used 
their machine on average for over four hours each night. 
Five experienced an increase in EE (mean % change), three of whom used their machine 
more than four hours a night on average.  
Between these two groups there was no significant difference in hours of CPAP use 




nights, and change in overnight energy expenditure; EE between stage one and stage three 
decreased more with greater CPAP compliance (p=0.017). A very similar result was found 
for percentage decrease in EE (p=0.014).  
Figures 5.1 and 5.2 respectively show the correlation between average hours CPAP use, 




Figure 5.1: Correlation between average hours of CPAP use per night, and 







Figure 5.2: Correlation between average hours of CPAP use per night, and change in 




Both body weight (kg) and BMI (kg/m2) had a positive correlation with EE per hour of 
sleep before beginning CPAP (Figure 5.3 and 5.4). BMI did not have a significant 






                                  
 
Figure 5.3: Correlation between Energy Expenditure and body weight (Kg) before 
beginning CPAP treatment 
 
                                
 
Figure 5.4: Correlation between Energy Expenditure and BMI (kg/m2) before 














































































Figure 5.5: Correlation between BMI, and change in Energy Expenditure per hour 



















Energy expenditure at baseline (before CPAP) ranged from 205 KJ/hour to 516 KJ/hour. 
Three control subjects who trialed the SenseWear devices overnight had an average EE of 
254.1kj/hour. Two subjects had an EE/hour value lower than this before CPAP. This is 

















Figure 5.7: Correlation between Energy Expenditure and Apnoea-Hypopnoea Index 
 
 
5.3.2 Energy Intake 
 
Average EI was 9629 KJ per day in stage one, and 9271 KJ per day in stage three. As was 
shown in Table 5.5, there was no significant difference between these two values. Some 
participants however did show a dramatic change in EI between the two phases. This can 
be seen below in Figure 5.8, which shows the EI of each participant in each phase. 
Takeaways and fast food were consumed more often during the phase where the 

















































This study was the first in New Zealand to attempt to measure energy intake and energy 
expenditure in OSA before and after CPAP treatment initiation. Some results of this study 
are inconsistent with results of previous overseas studies (Hins et al., 2006, Stenlof et al., 
1996); we found for this group of subjects no significant difference between the energy 
expended overnight before and after initiating CPAP, but that decreased EE was 
associated with greater CPAP use. There is evidence from this study that CPAP has a role 
in decreasing energy expenditure in people with OSA, particularly in those who are more 
compliant with the treatment. The implications are that in the long-term, this could result 
in potentially significant weight gain if energy intake and/or daytime energy expenditure 
remain unchanged.  
 
Though this study was only of short duration, the average energy intake of participants did 
not significantly change before and after CPAP initiation. This adds to the body of 
evidence that people with OSA do not necessarily change their eating habits or lifestyle 
upon diagnosis of OSA and initiating CPAP treatment. Therefore structured intervention 
and guidance by a Health professional is needed for this to happen, as noted in previous 
research. (Johansson et al., 2011, Chirinos et al., 2014, Hood et al., 2013, Thomasouli et 
al., 2013). 
 
Individuals with a higher BMI have a higher metabolic rate, as they have greater fat-free 




and suddenly, or gradually over time), loss of fat-free mass will occur and their metabolic 
rate will consequently decrease (Prentice, 2012). In this study, changes in overnight 
energy expenditure are attributed to CPAP use, as there was no significant change in EI. 
Other studies have not measured EI directly so it is uncertain if participants changed their 
diet at all during the study period. In terms of diet and exercise counselling, the meta-
analysis by Drager et al. found that CPAP alone was associated with change in body 
weight, regardless of the counselling (Drager et al., 2014). However, as EI was not 
measured it is difficult to know if participants experienced any change in EI. 
 
This study had several limitations which may have contributed to the lack of statistically 
significant difference between EE per hour of sleep, before and after CPAP initiation. 
Firstly, sample size was smaller than anticipated, as four of the fifteen subjects did not 
complete the protocol. The study by Stenlof et al. also had only 11 participants, but the 
study ran for three months (Stenlof et al., 1996), possibly allowing further time for 
adaptations to occur compared to the current study. Participants in the current study used 
CPAP on average for less than one month before the next stage of data collection. The 
reason for this is that this study was designed as a pilot and was constrained by the 
candidate’s research period of five months. 
 
A second limitation of this study was CPAP compliance. Only four participants used 
CPAP for at least four hours or more for all three nights. Three further participants used 
CPAP for over four hours, during one night only. Previous studies have defined CPAP 




et al., 2011). Therefore almost two thirds of participants in this study were not compliant 
with CPAP. Some participants explained when returning materials at the end of stage 
three that they had used their machine “very little” due to being unwell. Given this study 
involved the use of CPAP while measuring energy expenditure, the level of compliance 
may not have been high enough to show significant differences in the small sample. The 
proposed ways in which EE increases during OSA (Chronic Intermittent Hypoxia and 
increased work of breathing) would still have been an issue during this period. 
Even though BMI was not significantly related to EE, there is a trend for participants with 
the higher BMI’s to have greater overnight EE (before initiating CPAP) compared to 
subjects with lower BMI’s. Those with higher BMI’s (>30kg/m2) tended to experience a 
greater decrease in EE with CPAP treatment than participants with lower BMI’s. If the 
current study was repeated with a larger sample size, this might show significance, and 
demonstrate that those with a higher BMI are at a greater disadvantage for attempting to 
lose weight when they begin CPAP treatment.  
 
Data collection success rate was high, as only 15 minutes of data were lost during sleep 
from one participant while wearing the armband, due to the SenseWear® being too loose 
on his arm. This also happened in a study in adolescents published this year by Roane et 
al, which also used SenseWear® devices (Roane et al., 2015). No more than 2-3 minutes 
of data were lost from other participants during sleep in the current study. 
Our results showed no difference in Total Sleep Time between stages one and three. This 
was measured subjectively via sleep diary, and objectively via SenseWear. Therefore we 




surprising due to the poor CPAP compliance. Roane et al also measured variability in 
Total Sleep Time (TST), but only did so objectively through use of SenseWear® and other 
actigraph devices. 
 
Several of the participants overnight EE recordings were within the range of control 
subjects, therefore it is likely that they had less room to decrease their overnight EE to 
start with i.e. a floor effect was seen, and this would have contributed to the lack of 
statistical significance. 
 
Despite these limitations, there were major strengths in the study design. A major strength 
was the use of the SenseWear® device to assess sleep patterns. SenseWear® has high 
reliability and validity when detecting sleep parameters (Sunseri et al., [No date]). A 
recent study in a group of 20 US adolescents showed that SenseWear® was accurate in 
estimating sleep duration for groups of people. Compared to PSG, there were no 
significant differences for any of the sleep parameters measured (Roane et al., 2015). An 
internal company SenseWear® research paper found that sleep data from SenseWear® 
had a 91.9% similarity to PSG data (Sunseri et al., [No date]). The participants sleep and 
wake times for stage one and two of data recording that were detected by the device were 
close to those recorded in the sleep diaries.  
 
Diet records are a validated method of measuring energy intake and considered the “Gold 
Standard” in diet assessment (Gibson, 2005). Estimated records are not as reliable as 




weighed records would not have been appropriate for this population due to the high level 
of respondent burden. The diet records were checked for completeness when handed in, 
and participants were asked via email or in person during a clinic visit about any 
potentially incomplete data to ensure the diet data collected was as accurate as possible. 
 
A further limitation of the study is that SenseWear® may not be completely accurate in 
measuring EE in the current study’s population. In terms of EE data, it has been found in 
previous trials that SenseWear® provides valid and reliable EE estimates for men and 
women of healthy body weight, but that individual error is large (Fruin and Rankin, 2004), 
and that SenseWear® is not the most accurate method of measuring EE in obese people 
(Papazoglou et al., 2006). SenseWear® has been shown to be reliable when used with 
subjects with varied medical conditions (Andre et al,. 2006). However O’Driscoll et al 
point out that SenseWear has not specifically been validated for EE in OSA patients 
(O’Driscoll et al., 2013). As this was a pre- and post- trial on individuals, it is possible that 
this error was low as data was paired. 
 
The days of the week where data were collected may not be representative of usual energy 
intake or sleep pattern. For most participants two weekend days were included as part of 
the three days of recording. This was often because their PSG was scheduled for a Sunday 
or Monday evening and so they were required to come into the clinic on Thursday or 
Friday to collect the diaries and SenseWear. Weekends are a time of the week when EI is 
greatest and EE lower, compared to weekdays (Racette et al., 2008, Gibson, 2005). Some 




participant had a high EI in stage one due to a high intake of alcohol. Takeaway and fast 
food consumption that occurred during one recorded weekend, but not during the other 
weekend, also account for some difference between the two stages. Another participant 
had a very low energy intake in stage one (2540KJ/day) as he had decided at the time to 
severely restrict food intake to try and lose weight. However in stage three his EI was 
much higher (9205KJ/day). To ensure equal comparison between stage one and stage 
three, the days of the week recorded in each stage were the same. 
 
The present study had no control group of overweight/obese patients without OSA, or 
OSA patients not using CPAP, also due to time constraints and availability of equipment. 
In particular there would not have been enough SenseWear® devices available to include 
a control group. 
Implications for further research 
A larger sample size and a longer study period would allow further time for changes to 
manifest. A longer study period may allow changes in metabolism to become established, 
and compliance with treatment to be more consistent. Another factor to consider would be 
carrying out the study during a time of year when illness from the cold virus is not so 
prevalent, as this was cited by participants as a major reason for not using CPAP at least 
four hours per night. 
 
A study which involved a gold standard measure of energy expenditure may also yield 
different results. This would involve admitting patients to a metabolic chamber each night 




be a far more burdensome and expensive study, and would provide data in a controlled 
clinical setting rather than a free-living one. Incorporating Sham-CPAP into the study 
would provide evidence for changes in EE over time. This technology was not available to 
the current study. A control group of overweight/obese subjects without OSA is also 
something to be considered for future research. This would allow comparison of energy 
expenditure between the two groups, and further determine the extent to which EE is 
increased in OSA, and how much it decreases with CPAP treatment. 
Conclusions 
This study found that CPAP treatment significantly decreased both the change and 
percentage change in EE between stage one and stage three (before and during CPAP 
treatment, respectively) when controlling for CPAP use. There was no change in 
participants TST or EI between stage one and three. These findings indicate there is the 
potential for weight gain to occur on CPAP treatment, particularly if EI and daytime EE 
remain unchanged. 
Limitations of this study were poor CPAP compliance and small sample size. However 
some individual results show a drastic reduction in EE upon establishing CPAP, with 
average compliance over four hours per night. These subjects are at significant risk of 
weight gain. 
This study highlights the need for further studies, which have a longer time frame and 
greater number of participants, to provide more evidence on the relationship between 
CPAP and its effect on EE. It also shows the need for a multidisciplinary approach to the 
use of CPAP for the treatment of OSA. Specific dietary input in this group is likely to be 




7. Application to Dietetic Practice 
 
As the proportion of overweight and obese New Zealanders increases, so too will the 
proportion of our population with OSA. Currently, newly diagnosed patients are advised 
by their Doctor to lose weight as this can help improve OSA severity; however no specific 
nutrition and lifestyle advice or intervention is necessarily given to patients to help 
encourage and motivate lifestyle change. 
 
 This study provides some evidence toward the need for intensive lifestyle intervention to 
be administered to people with OSA who are overweight or obese. Treatment with CPAP 
alone will not lead to lifestyle change or weight reduction for OSA patients. Patients need 
to be targeted for nutrition and lifestyle intervention shortly after OSA diagnosis, so that 
along with CPAP, there is further improvement in quality of life.  
 
Firstly, there should be promotion of OSA as a health issue and co-morbidity of obesity to 
increase awareness amongst Dietitians.  
 
Continuing to advocate for, and implement, public health policy and legislation to tackle 
rising rates of overweight and obesity is a major way Dietitians can help prevent people 
from developing OSA. They can also work with stakeholders to help implement 
community initiatives, for example Fruit and Vegetable co-ops, which in turn Dietitians 





Dietitians can give evidence-based nutrition and weight loss advice and interventions to 
help clients with weight loss or weight maintenance, to prevent OSA from developing or 
to improve severity for current OSA patients. This will also importantly aid in prevention 
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A. Participant Information Sheet (PIS) 
B. Ethics form 
C. Consent form 
D. Email sent to participant if it was the first form of contact 
E. Email sent to participant if first contact made via phone 
F. University of Otago 4 day Food Record with instructions 
G. WellSleep Sleep diary and instructions 
H. Photo of SenseWear® device on armband 
I. Example of 24 hour EE graph produced by SenseWear Professional program 




















































































































































My name is Stacey Edwards and I am a Master of Dietetics student at the University of 
Otago. I am doing my thesis at the Wellsleep Clinic at Bowen Hospital. 
 
I am currently looking for people willing to participate in my research. The study is 
looking at energy (calorie) expenditure changes in people with Obstructive Sleep Apnoea 
(OSA) before and after starting treatment with a CPAP machine.  Some people when they 
start using the CPAP device lose weight and some gain weight. The study hopes to 
understand more about how this weight change occurs and hopefully provide information 
to assist with weight loss after treatment with this device (CPAP) has been started. 
 
I have attached a Participant Information Sheet, and also a flowchart that shows the 
timeline of events over the course of the study. Please have a read over these and think 
about whether or not you would be interested in participating. The study would require 
you to briefly come into the clinic for approximately 20 minutes to have a debrief with 
me and explanation on using the armband and food/sleep diaries (the first box on the flow 
chart). We will reimburse you with a $20 petrol voucher if you do manage to complete 3 
full days of food/sleep diaries.  
 
I will give you a call later this week to have a chat and ask if you would be interested in 
participating. It is entirely up to you whether or not you want to participate. If you do 
agree to participate but later change your mind, you can drop out of the study at any time 
you choose with no disadvantage or consequence for yourself. 
 
Alternatively, you can reply to my email to let me know of your decision, and if you wish 
to participate we can sort out a time for you to come in to see me. If you have any 
questions then don’t hesitate to get in touch. 
















































Thank you for taking the time to chat to me today. As I said on the phone, my name is 
Stacey Edwards and I am a Master of Dietetics student at the University of Otago. I am 
doing my thesis at the Wellsleep Clinic at Bowen Hospital. 
 
The study is looking at energy (calorie) expenditure changes in people with Obstructive 
Sleep Apnoea (OSA) before and after starting treatment with a CPAP machine.  Some 
people when they start using the CPAP device lose weight and some gain weight. The 
study hopes to understand more about how this weight change occurs and hopefully 
provide information to assist with weight loss after treatment with this device (CPAP) has 
been started. 
 
I have attached a Participant Information Sheet, and also a flowchart that shows the 
timeline of events over the course of the study. As we discussed, the study would require 
you to briefly come into the clinic (for approximately 15-20 minutes) to have a debrief 
with me and explanation on using the armband and food/sleep diaries (the first box on the 
flow chart). We will reimburse you with a $20 petrol voucher if you do manage 
to complete 3 full days of food/sleep diaries.  
 
If later you change your mind about participating, you can drop out of the study at any 
time you choose with no disadvantage or consequence for yourself. 
 
If you have any questions then don’t hesitate to get in touch. 
I look forward to seeing you on (day of week). Don't hesitate to email me back if you are 







































































































































































































































































Example of 24 hour EE graph produced by SenseWear Professional 











































The yellow lines show energy expenditure (measured in KJ), and blue lines show activity 
and sleep. The top blue row is ‘sedentary’; second row is ‘light’ activity; third row is 
‘moderate’ activity. The last two lines are ‘lying down’ and ‘sleep’ respectively. 
All occurred within a 24 hour period. 
 
Total energy expenditure, step count, total sleep time etc. are displayed along the bottom 
in white type. 
 
 
